Amgen, Inc. (NASDAQ:AMGN) saw unusually large options trading on Tuesday. Stock investors bought 259,602 call options on the company. This is an increase of approximately 3,082% compared to the average daily volume of 8,158 call options.

AMGN has been the subject of several analyst reports. BMO Capital Markets set a $230.00 price objective on Amgen and gave the company a “buy” rating in a report on Wednesday, July 31st. JPMorgan Chase & Co. reissued a “hold” rating on shares of Amgen in a report on Friday, August 9th. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Mizuho reissued a “buy” rating and issued a $208.00 price objective on shares of Amgen in a report on Monday, July 1st. Finally, Evercore ISI reissued a “hold” rating on shares of Amgen in a report on Sunday. Nine equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Amgen presently has a consensus rating of “Buy” and a consensus price target of $211.78.

Shares of Amgen stock traded down $4.42 on Wednesday, hitting $201.70. The company’s stock had a trading volume of 782,296 shares, compared to its average volume of 3,052,886. The company has a quick ratio of 2.60, a current ratio of 2.89 and a debt-to-equity ratio of 2.58. Amgen has a 1 year low of $166.30 and a 1 year high of $211.90. The firm’s fifty day moving average is $182.89. The firm has a market cap of $117.69 billion, a P/E ratio of 14.01, a price-to-earnings-growth ratio of 2.30 and a beta of 1.19.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The firm had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the previous year, the business earned $3.83 EPS. Amgen’s revenue for the quarter was down 3.1% compared to the same quarter last year. As a group, equities analysts forecast that Amgen will post 14.23 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Investors of record on Thursday, August 15th will be paid a $1.45 dividend. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $5.80 annualized dividend and a dividend yield of 2.88%. Amgen’s dividend payout ratio is presently 40.28%.

In other news, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total value of $77,792.00. Following the completion of the transaction, the director now owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total value of $375,160.00. Following the completion of the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at approximately $3,064,306.88. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,425 shares of company stock valued at $804,312. 0.25% of the stock is currently owned by insiders.

Institutional investors have recently made changes to their positions in the stock. Pathstone Family Office LLC increased its stake in Amgen by 7.4% during the 2nd quarter. Pathstone Family Office LLC now owns 9,228 shares of the medical research company’s stock worth $1,701,000 after buying an additional 634 shares in the last quarter. Marietta Wealth Management LLC increased its stake in Amgen by 6.3% during the 2nd quarter. Marietta Wealth Management LLC now owns 16,918 shares of the medical research company’s stock worth $3,118,000 after buying an additional 998 shares in the last quarter. Private Advisor Group LLC increased its stake in Amgen by 4.0% during the 2nd quarter. Private Advisor Group LLC now owns 38,488 shares of the medical research company’s stock worth $7,093,000 after buying an additional 1,494 shares in the last quarter. ETF Managers Group LLC increased its stake in Amgen by 139.0% during the 2nd quarter. ETF Managers Group LLC now owns 11,235 shares of the medical research company’s stock worth $2,067,000 after buying an additional 6,535 shares in the last quarter. Finally, AMP Capital Investors Ltd increased its stake in Amgen by 8.9% during the 2nd quarter. AMP Capital Investors Ltd now owns 338,193 shares of the medical research company’s stock worth $62,236,000 after buying an additional 27,506 shares in the last quarter. Hedge funds and other institutional investors own 78.96% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: What is the Coverage Ratio?

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.